MEG
RPRX icon

Millstone Evans Group’s Royalty Pharma RPRX Stock Holding History

Millstone Evans Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.5K Hold
98
– – ﹤0.01% 666
2026
Q1 		$4.7K Hold
98
– – ﹤0.01% 660
2025
Q4 		$3.79K Hold
98
– – ﹤0.01% 683
2025
Q3 		$3.46K Hold
98
– – ﹤0.01% 679
2025
Q2 		$3.53K Hold
98
– – ﹤0.01% 622
2025
Q1 		$3.05K Hold
98
– – ﹤0.01% 662
2024
Q4 		$2.5K Buy
+98
New +$2.6K ﹤0.01% 634

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millstone Evans Group's RPRX Position: Q2 2026 in Review

Millstone Evans Group held its Royalty Pharma (RPRX) position steady in Q2 2026 at 98 shares worth $5.5K. The position accounts for ﹤0.01% of the portfolio, ranked #666.

Millstone Evans Group first reported a position in RPRX in Q4 2024 and has held it in 7 quarters since. 498 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Millstone Evans Group held 98 shares of Royalty Pharma worth $5.5K as of Q2 2026.
  • Millstone Evans Group left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up ﹤0.01% of Millstone Evans Group's portfolio in Q2 2026, its #666 holding.
  • Millstone Evans Group first reported a position in Royalty Pharma in Q4 2024 and has held it in 7 quarters since.
  • 498 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Millstone Evans Group's 13F filing for Q2 2026, filed 11 Aug 2026.